For nearly 75 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies.
When you join our family, you will have a significant impact on the health and well-being of people across the globe.
Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform.
In return, we'll help you build a career that you can feel passionate about.Job SummaryFor 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies.
When you join our family, you will have a significant impact on the health and well-being of people across the globe.
Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform.
In return, we'll help you build a career that you can feel passionate about.
Job Summary We are looking for a highly motivated home-based salesperson in the North of Italy.
In this role, you will be responsible for achieving quarterly and annual sales targets for the assigned region (North of Italy and Italian speaking part of Switzerland) for all Charles River Microbial Solutions products and services into commercial accounts.Job Qualifications Work with internal teams (SPS, PM, Management, etc.)
to increase market share and revenue at assigned accounts.
With direction from management, generate account-specific sales strategies to sell all company products and services.
Work with management to prepare and provide accurate account forecasts for assigned accounts/territories when required by management.
Develop and qualify account leads through frequent customer contact and prospecting.
Build relationships with customers to influence the acceptance and use of company products and services.
Communicate available product and services and inform customers of new products and services in a timely manner.
Handle initial inquires and qualify all prospective opportunities.
About Microbial SolutionsOur Microbial Solutions business group has a comprehensive portfolio of endotoxin testing, microbial detection and microbial identification products and services is unlike any other, and has been purposefully designed to meet the complex and ever-changing needs of the industry.
We help clients to ensure product safety and quality with easy-to-use yet robust testing solutions that satisfy regulatory requirements, support critical decision making and improve operational efficiencies.
About Charles RiverCharles River is an early-stage contract research organization (CRO).
We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development.
Charles River also provides a suite of products and services to support our clients' clinical laboratory testing needs and manufacturing activities.
Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 20,000 employees within 110 facilities in over 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client's unique challenges.
Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world.
At Charles River, we are passionate about our role in improving the quality of people's lives.
Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.
We have proudly supported the development of 86% of the drugs approved by the FDA in 2021.